STAB
Statera BioPharma Inc

7,586
Loading...
Loading...
Statera Biopharma, Inc. is a clinical-stage biopharmaceutical company, which engages in developing novel immunotherapies targeting autoimmune, neutropenia/anemia, emerging viruses and cancers based on a proprietary platform designed to rebalance the body's immune system and restore homeostasis. Its proprietary product toll-like receptor (TLR) agonists in the biopharmaceutical industry with TLR4 and TLR9 antagonists, and the TLR5 agonists, Entolimod and GP532 have applications in mitigation of radiation injury and neutropenia an anemia. The firm is developing therapies designed to directly elicit within patients a robust and durable response of antigen-specific killer T-cells and antibodies, thereby activating essential immune defenses against autoimmune, inflammatory, infectious diseases, and cancers. It has clinical programs for Crohn’s disease (STAT-201), hematology (Entolimod), pancreatic cancer (STAT-401) and COVID-19 (STAT-205) in addition to expansion into fibromyalgia and multiple sclerosis. The company was founded by Andrei V. Gudkov and Yakov Kogan on June 5, 2003 and is headquartered in Fort Collins, CO.
Sector:
Health Technology
Industry:
Biotechnology
Employees:
N/A

Frequently Asked Questions

What is Market Cap of Statera BioPharma Inc?
What is the 52-week high for Statera BioPharma Inc?
What is the 52-week low for Statera BioPharma Inc?
What is Statera BioPharma Inc stock price today?
What was Statera BioPharma Inc stock price yesterday?
What is the 50-day moving average of Statera BioPharma Inc?

Latest STAB News

View

Advertisement. Remove ads.

Advertisement. Remove ads.